Diabetes Management 2026: Comprehensive Evidence-Based Approach
Glycemic Targets by Patient Population
For most adults with type 2 diabetes, target HbA1c between 7.0–8.0%, moving away from the traditional <7% goal to reduce hypoglycemia risk and treatment burden. 1, 2
Healthy Older Adults (≥65 years)
- Target HbA1c <7.0–7.5% (or TIR 70% with time below range <4%) for otherwise healthy older adults with few stable chronic illnesses, intact cognition, and functional independence. 1
Intermediate/Complex Health Older Adults
- Target HbA1c <8.0% (or TIR 50% with time below range <1%) for those with significant cognitive/functional limitations, frailty, severe comorbidities, or unfavorable medication risk-benefit ratio. 1
Very Complex/Poor Health Older Adults
- Focus exclusively on avoiding hypoglycemia and symptomatic hyperglycemia rather than achieving specific HbA1c targets in those with very complex or poor health. 1
Deintensification Threshold
- Deintensify glucose-lowering therapy immediately when HbA1c falls below 6.5% to prevent hypoglycemia and overtreatment. 1, 2
First-Line Pharmacologic Therapy
Initiate metformin immediately at diagnosis combined with lifestyle modifications for all adults with type 2 diabetes unless contraindicated. 1, 2
- Continue metformin long-term as the foundation of therapy regardless of subsequent medication additions 1
- Monitor for vitamin B12 deficiency during long-term use, particularly if anemia or peripheral neuropathy develops 3, 4
- Metformin is safe when eGFR ≥30 mL/min/1.73 m² 2
Second-Line Therapy: Organ-Protection Algorithm
When HbA1c remains above target after 3 months of metformin plus lifestyle modifications, select second-line agents based on comorbidities rather than glycemic level alone. 1, 2
SGLT2 Inhibitors (Preferred When):
Add SGLT2 inhibitor for patients with heart failure (any ejection fraction), chronic kidney disease (eGFR 20–60 mL/min/1.73 m² and/or albuminuria), or when cardiovascular mortality reduction is the primary goal. 1, 2
- SGLT2 inhibitors reduce heart failure hospitalizations by 18–25% 2
- They slow CKD progression by 24–39% and reduce cardiovascular events 2
- Glycemic efficacy diminishes when eGFR <45 mL/min/1.73 m²; use primarily for organ protection below this threshold 2
GLP-1 Receptor Agonists (Preferred When):
Add GLP-1 RA for patients with elevated stroke risk, need for substantial weight loss, advanced CKD (eGFR <30 mL/min/1.73 m²), or when all-cause mortality reduction is the primary goal. 1, 2
- GLP-1 RAs reduce stroke incidence by 12–26% 2
- High-potency GLP-1 RAs achieve >5% body weight loss in the majority of users 2
- For patients with BMI >25, tirzepatide (dual GIP/GLP-1 RA) is favored, achieving average weight loss of 8.5 kg with approximately 67% achieving ≥10% weight reduction 2, 3
Critical Medication Combinations to Avoid:
Do not combine GLP-1 RAs (or tirzepatide) with DPP-4 inhibitors as there is no added glucose-lowering benefit beyond the GLP-1 RA alone. 1
Newly Diagnosed Type 2 Diabetes
Consider insulin as the first injectable if symptoms of hyperglycemia are present, when A1C >10% (>86 mmol/mol) or blood glucose ≥300 mg/dL (≥16.7 mmol/L), or when type 1 diabetes is a possibility. 1
- For all others, initiate metformin plus lifestyle modifications 1
- If A1C is 1.5–2.0% above individualized goal, incorporate high-glycemic-efficacy therapies (GLP-1 RAs, tirzepatide, or SGLT2 inhibitors) to reduce need for agents that increase hypoglycemia and weight gain 1
Insulin Regimens
Initiating Basal Insulin:
When basal insulin is needed, use human NPH or long-acting insulin analog, but prioritize starting GLP-1 RA or tirzepatide first if not already prescribed, as these may be sufficient with lower hypoglycemia risk. 1
Intensifying Insulin Therapy:
Monitor for signs of overbasalization: basal dose exceeding 0.5 units/kg/day, significant bedtime-to-morning or postprandial-to-preprandial glucose differential, hypoglycemia occurrences, or high glycemic variability. 1
- When overbasalization is suspected, promptly reevaluate and add prandial insulin rather than continuing to increase basal doses 1
- Prandial insulin options include rapid-acting analogs, ultra-rapid-acting analogs, short-acting human insulin, or inhaled human insulin 1
Insulin Deintensification:
When starting insulin, reassess the need for and/or dose of sulfonylureas and meglitinides to minimize hypoglycemia risk and treatment burden. 1
- For people on GLP-1 RA and basal insulin combination, consider fixed-ratio combination products (IDegLira or iGlarLixi) 1
Type 1 Diabetes Technology
Continuous Glucose Monitoring (CGM):
Use CGM in older adults with type 1 diabetes to reduce hypoglycemia risk, particularly time below 70 mg/dL. 1
Automated Insulin Delivery (AID):
Consider AID systems for older adults with type 1 diabetes when ability and resources permit, as they improve time in range and reduce hypoglycemia compared to sensor-augmented pump therapy. 1
- The ORACL trial demonstrated significant improvements in TIR and small but significant decreases in hypoglycemia with AID in older adults (mean age 67 years) 1
- A recent trial in older adults with type 2 diabetes using multiple daily injections showed 27% increase in TIR over 12 weeks with AID plus tailored home health care services 1
Chronic Kidney Disease (Stages 3–5)
Stage 3 CKD (eGFR 30–60 mL/min/1.73 m²):
Prescribe SGLT2 inhibitor for patients with eGFR 20–60 mL/min/1.73 m² and/or albuminuria to slow CKD progression and reduce cardiovascular events. 1, 2
- Continue metformin when eGFR ≥30 mL/min/1.73 m² 2
- SGLT2 inhibitors reduce CKD progression by 24–39% 2
Advanced CKD (eGFR <30 mL/min/1.73 m²):
Use GLP-1 RA as the preferred glucose-lowering agent when eGFR <30 mL/min/1.73 m² and SGLT2 inhibitors are unsuitable, due to low hypoglycemia risk. 2
- Discontinue metformin when eGFR <30 mL/min/1.73 m² 2
Atherosclerotic Cardiovascular Disease (ASCVD)
For people with type 2 diabetes and established ASCVD or indicators of high ASCVD risk, prescribe SGLT2 inhibitor and/or GLP-1 RA with demonstrated cardiovascular benefit regardless of baseline HbA1c. 1
- When selecting GLP-1 RAs, consider individual preference, A1C lowering, weight-lowering effect, and frequency of injection 1
- If CVD is present, select GLP-1 RA with proven CVD benefit; oral or injectable formulations are appropriate 1
Heart Failure
Prescribe SGLT2 inhibitor for all patients with heart failure (reduced or preserved ejection fraction) to reduce heart failure hospitalizations by 18–25%. 1, 2
- This recommendation applies irrespective of baseline glycemic control 1
Overweight/Obese Individuals (BMI >25)
For adults with type 2 diabetes and BMI >25, initiate metformin plus lifestyle modifications, then add tirzepatide if HbA1c remains above 7% after 3 months, as this combination provides superior glycemic control and substantial weight loss. 3
- Tirzepatide produces mean weight loss of 8.47 kg, with up to 67% achieving ≥10% weight reduction 3
- Prescribe ≥150 minutes/week of moderate-intensity aerobic exercise plus 2–3 sessions/week of resistance training on nonconsecutive days 1, 2, 3
- For older adults with type 2 diabetes, overweight/obesity, and capacity to exercise safely, intensive lifestyle intervention focused on dietary changes, physical activity, and modest weight loss (5–7%) improves quality of life, mobility, physical functioning, and cardiometabolic risk 1
Older Adults (≥65 Years): Medication Selection
Select medications with low hypoglycemia risk (metformin, SGLT2 inhibitors, GLP-1 RAs, DPP-4 inhibitors) for older adults, specifically those with hypoglycemia risk factors. 1, 2
Deintensification in Older Adults:
Deintensify hypoglycemia-causing medications (insulin, sulfonylureas, meglitinides) or switch to medication classes with low hypoglycemia risk for individuals at high risk for hypoglycemia. 1
- Overtreatment is common in older adults and should be avoided 1
- Simplify complex treatment plans (especially insulin) to reduce hypoglycemia risk, polypharmacy, and treatment burden 1
Organ Protection in Older Adults:
In older adults with type 2 diabetes and established or high risk of ASCVD, heart failure, and/or CKD, include agents that reduce cardiovascular and kidney disease risk irrespective of glycemia. 1
Cardiovascular Risk Factor Management
Hypertension:
Treat hypertension to individualized target levels in most older adults with diabetes, as treatment reduces cardiovascular events. 1, 2
- Target systolic/diastolic <140/80 mmHg for most adults with diabetes 2
- ACE inhibitors or ARBs are preferred first-line agents, especially with albuminuria 2
Lipid Management:
Target LDL-cholesterol <100 mg/dL (2.6 mmol/L) for most adults with diabetes; for those with established ASCVD, target LDL <70 mg/dL using high-intensity statin therapy. 2
- Prescribe statin therapy to all adults with diabetes who have history of myocardial infarction or are ≥40 years with additional cardiovascular risk factors 2
- In older adults, lipid-lowering therapy and antiplatelet agents may benefit those with life expectancies at least equal to the time frame of primary prevention or secondary intervention trials (2–6 years for statins) 1
Lifestyle Management for Older Adults
Recommend healthful eating with adequate protein intake for older adults with diabetes to prevent sarcopenia and frailty. 1
- Special attention should be paid to malnutrition risk, as it is associated with decreases in activities of daily living, grip strength, physical performance, cognition, and quality of life 1
- Recommend regular exercise including aerobic activity, weight-bearing exercise, and/or resistance training as tolerated in those who can safely engage in such activities 1
Cost-Effective Medication Choices
Routinely assess all people with diabetes for financial obstacles that could impede diabetes management, and work collaboratively to implement strategies to reduce costs. 1
- Consider costs of care and coverage when developing treatment plans to reduce risk of cost-related barriers to medication taking and self-management behaviors 1
- In adults with cost-related barriers, consider lower-cost medications (metformin, sulfonylureas, thiazolidinediones, human insulin) within the context of their risks for hypoglycemia, weight gain, cardiovascular and kidney events, and other adverse effects 1
Cost-Constrained Algorithm:
When newer agents are unaffordable, maximize sulfonylurea dose; if HbA1c remains >8%, add basal insulin and immediately reduce sulfonylurea dose by 50% to prevent severe hypoglycemia. 3, 4
Medication Reassessment Schedule
Reevaluate the medication regimen every 3–6 months, adjusting based on glycemic control, weight objectives, metabolic comorbidities, and hypoglycemia risk. 1, 2, 3, 4
- Treatment intensification, deintensification, or modification should not be delayed for people not meeting individualized treatment goals (avoid therapeutic inertia) 1, 3, 4
Critical Pitfalls to Avoid
Do not continue sulfonylureas or long-acting insulins once SGLT2 inhibitors or GLP-1 RAs achieve adequate glycemic control, as these older agents increase severe hypoglycemia risk without mortality benefit. 2, 3, 4
- Each new class of oral noninsulin agent added to metformin generally lowers A1C by approximately 0.7–1.0%; GLP-1 RAs or tirzepatide added to metformin usually result in 1–2% A1C lowering 1
- Do not delay treatment intensification when patients fail to meet glycemic targets—therapeutic inertia worsens long-term outcomes 1, 3, 4
- Screening for diabetes complications should be individualized in older adults, with particular attention to complications that would impair functional status or quality of life 1